A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Recruiting

Phase 1

BMS-986463A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Sponsor:

Bristol-Myers Squibb

Code:

NCT06476808

Conditions

High-grade Serous Ovarian Carcinoma (HGSOC)

Uterine Serous Carcinoma (USC)

Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BMS-986463

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-23. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2025-10-21.